Lexicon Pharmaceuticals CEO buys 30,064 shares

The CEO directly held 328,496 common shares after the November 6 purchase.

Available on EDGAR 11/09/2026 - 08:14 AM EST Accepted by SEC EDGAR 11/09/2026 - 08:13 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Lexicon Pharmaceuticals, Inc. (LXRX) Chief Executive Officer Michael Exton purchased 30,064 shares of common stock on November 6, 2026, at a weighted average price of $1.6631 per share. The purchases were made in multiple transactions at prices ranging from $1.63 to $1.67 per share. He directly held 328,496 shares after the purchase. No Rule 10b5-1 plan was reported.

Insider Trade Summary

Net Buyer: 30,064 shares

Net Buy 1 txn

Insider Exton Michael

Role Chief Executive Officer

Bought 30,064 shs ($50K)

Type	Security	Shares	Price	Value
Purchase	Common Stock F1	30,064	$1.6631	$50K

Holdings After Transaction: Common Stock — 328,496 shares (Direct)

Footnotes (1)

1. F1. Represents a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.63 to $1.67 per share. The reporting person hereby undertakes to provide to the issuer, a security holder of the issuer or the SEC staff, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote.

Key Figures

Common shares purchased: 30,064 shares Weighted average purchase price: $1.6631 per share Purchase price range: $1.63 to $1.67 per share +1 more

4 metrics

Common shares purchased 30,064 shares November 6, 2026

Weighted average purchase price $1.6631 per share November 6, 2026

Purchase price range $1.63 to $1.67 per share Multiple transactions

Direct shares held after purchase 328,496 shares After the November 6, 2026 purchase

Key Terms

weighted average price

1 terms

weighted average price financial

"Represents a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many LXRX shares did the CEO buy, and at what price?

Michael Exton, Lexicon Pharmaceuticals' CEO, purchased 30,064 common shares on November 6, 2026, at a weighted average price of $1.6631 per share. Individual purchase prices ranged from $1.63 to $1.67 per share.

How many LXRX shares did Michael Exton hold after the purchase?

After the November 6, 2026 purchase, CEO Michael Exton directly held 328,496 shares of common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Exton Michael

(Last) (First) (Middle)

2445 TECHNOLOGY FOREST BLVD

11TH FLOOR

(Street)

THE WOODLANDS TEXAS 77381

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LEXICON PHARMACEUTICALS, INC. [ LXRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/06/2026		P		30,064	A	$1.6631(1)	328,496	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.63 to $1.67 per share. The reporting person hereby undertakes to provide to the issuer, a security holder of the issuer or the SEC staff, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote.

	/s/ Michael Exton, Ph.D.	11/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)